aLaboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, “G. d'Annunzio” University of Chieti, Chieti, Italy bUrology Unit, Department of Medical, Oral and Biotechnological Sciences, “G. d'Annunzio” University of Chieti, Chieti, Italy cDivision of Urology, VCU Health, Richmond, VA, USA
Objective: Prostate cancer (PCa) patients might experience lower urinary tract symptoms as those diagnosed with benign prostatic hyperplasia (BPH). Some of them might be treated for their lower urinary tract symptoms instead of PCa. We aimed to test the effect of PCa versus BPH on surgical outcomes after transurethral prostate surgery, namely complication and mortality rates.
Methods: Within the American College of Surgeons National Surgical Quality Improvement Program database (2011-2016), we identified patients who underwent transurethral resection of the prostate, photoselective vaporization, or laser enucleation. Patients were stratified according to postoperative diagnosis (PCa vs. BPH). Univariable and multivariable logistic regression models evaluated the predictors of perioperative morbidity and mortality. A formal test of interaction between diagnosis and surgical technique used was performed.
Results: Overall, 34 542 patients were included. Of all, 2008 (5.8%) had a diagnosis of PCa. The multivariable logistic regression model failed to show statistically significant higher rates of postoperative complications in PCa patients (odds ratio: 0.9, 95% confidence interval: 0.7-1.1; p=0.252). Moreover, similar rates of perioperative mortality (p=0.255), major acute cardiovascular events (p=0.581), transfusions (p=0.933), and length of stay of more than or equal to 30 days (p=0.174) were found. Additionally, all tests failed to show an interaction between post-operative diagnosis and surgical technique used.
Conclusion: Patients diagnosed with PCa do not experience higher perioperative morbidity or mortality after transurethral prostate surgery when compared to their BPH counterparts. Moreover, the diagnosis seems to not influence surgical technique outcomes.
. [J]. Asian Journal of Urology, 2024, 11(1): 48-54.
Michele Marchioni, Giulia Primiceri, Alessandro Veccia, Marta Di Nicola, Umberto Carbonara, Fabio Crocerossa, Ugo Falagario, Ambra Rizzoli, Riccardo Autorino, Luigi Schips. Transurethral prostate surgery in prostate cancer patients: A population-based comparative analysis of complication and mortality rates. Asian Journal of Urology, 2024, 11(1): 48-54.
Multivariable logistic regression model (BPH as reference)
BPH (n=32 534)
PCa (n=2008)
OR (95% CI)
p-Value
Primary outcome
Postoperative complications
2076 (6.4)
124 (6.2)
0.9 (0.7-1.1)
0.252
Secondary outcome
Perioperative mortality
71 (0.2)
3 (0.1)
0.5 (0.1-1.4)
0.255
Major acute cardiovascular event
207 (0.6)
17 (0.8)
1.2 (0.7-1.8)
0.581
Transfusion
269 (0.8)
26 (1.3)
1.0 (0.7-1.5)
0.933
Length of stay ≥30 days
63 (0.2)
8 (0.4)
1.7 (0.7-3.3)
0.174
[1]
Gravas S, Cornu JN, Gacci M, Gratzke C, Hermann TRW, Mamoulakis C, et al. EAU guidelines on management of nonneurogenic male LUTS. Uroweb; 2022. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/. [Accessed 16 August 2022].
[2]
Gondran-Tellier B, McManus R, Sichez PC, Akiki A, Gaillet S, Toledano H, et al. Efficacy and safety of surgery for benign prostatic obstruction in patients with preoperative urinary catheter. J Endourol 2021; 35:102-8.
doi: 10.1089/end.2020.0704
[3]
Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 2022; 5:e222246. https://doi.org/10.1001/jamanetworkopen.2022.2246.
[4]
Banerji JS, Wolff EM, Massman JD, Odem-Davis K, Porter CR, Corman JM. Prostate needle biopsy outcomes in the era of the U.S. Preventive Services Task Force recommendation against prostate specific antigen based screening. J Urol 2016; 195:66-73.
doi: 10.1016/j.juro.2015.07.099
pmid: 26254722
[5]
Capogrosso P, Capitanio U, Vertosick EA, Ventimiglia E, Chierigo F, Oreggia D, et al. Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia. Urology 2018; 122:152-7.
doi: S0090-4295(18)30783-0
pmid: 30138683
[6]
Porcaro AB, Tafuri A, Inverardi D, Amigoni N, Sebben M, Pirozzi M, et al. Incidental prostate cancer after transurethral resection of the prostate: analysis of incidence and risk factors in 458 patients. Minerva Urol Nefrol 2021; 73:471-80.
[7]
Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D’Amico AV, et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010—2015. JAMA 2019; 321:704-6.
doi: 10.1001/jama.2018.19941
[8]
Shevach J, Weiner A, Morgans AK. Quality of lifeefocused decision-making for prostate cancer. Curr Urol Rep 2019; 20:57. https://doi.org/10.1007/s11934-019-0924-2.
doi: 10.1007/s11934-019-0924-2
[9]
Pompe RS, Tilki D, Preisser F, Leyh-Bannurah S-R, Bandini M, Marchioni M, et al. Survival benefit of local versus no local treatment for metastatic prostate cancerdImpact of baseline PSA and metastatic substages. Prostate 2018; 78:753-7.
doi: 10.1002/pros.v78.10
[10]
Tan YG, Pang L, Khalid F, Poon R, Huang HH, Chen K, et al. Local and systemic morbidities of de novo metastatic prostate cancer in Singapore: insight from 685 consecutive patients from a large prospective Uro-oncology registry. BMJ Open 2020; 10:e034331. https://doi.org/10.1136/bmjopen-2019-034331.
doi: 10.1136/bmjopen-2019-034331
[11]
Marchioni M, Cindolo L, Di Nicola M, Schips L, De Sio M, Lima E, et al. Major acute cardiovascular events after transurethral prostate surgery: a population-based analysis. Urology 2019; 131:196-203.
doi: S0090-4295(19)30457-1
pmid: 31145946
[12]
Petersen LJ. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines. Cancer Treat Rev 2009; 35:754-64.
doi: 10.1016/j.ctrv.2009.08.009
pmid: 19762155
[13]
Quintana RA, Monlezun DJ, Davogustto G, Saenz HR, Lozano-Ruiz F, Sueta D, et al. Outcomes following percutaneous coronary intervention in patients with cancer. Int J Cardiol 2020; 300:106-12.
doi: S0167-5273(19)32714-7
pmid: 31611091
[14]
Klaassen Z, Wallis CJD, Lavallée LT, Violette PD. Perioperative venous thromboembolism prophylaxis in prostate cancer surgery. World J Urol 2020; 38:593-600.
doi: 10.1007/s00345-019-02705-x
pmid: 30840115
[15]
De Nunzio C, Lombardo R, Autorino R, Cicione A, Cindolo L, Damiano R, et al. Contemporary monopolar and bipolar transurethral resection of the prostate: prospective assessment of complications using the Clavien system. Int Urol Nephrol 2013; 45:951-9.
doi: 10.1007/s11255-013-0476-1
pmid: 23722819
[16]
Cavanaugh JE, Neath AA. The Akaike information criterion: background, derivation, properties, application, interpretation, and refinements. WIREs Computational Statistics 2019; 11:e1460. https://doi.org/10.1002/wics.1460.
[17]
Jibara G, Sjoberg DD, Stearns GL, Stabholz Y, Fathollahi A, Leddy LS, et al. Photoselective vaporization of the prostate in the management of lower urinary tract symptoms in prostate cancer patients on active surveillance. Urology 2021; 156:225-30.
doi: 10.1016/j.urology.2021.01.040
pmid: 33539897
[18]
Choi SY, Ryu J, You D, Jeong IG, Hong JH, Ahn H, et al. Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study. J Cancer Res Clin Oncol 2018; 144:751-8.
doi: 10.1007/s00432-018-2597-5
pmid: 29417257
[19]
Pelletier J, Cyr SJ, Julien AS, Fradet Y, Lacombe L, Toren P. Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. Urol Oncol 2018; 36:363.e7-11.https://doi.org/10.1016/j.urolonc.2018.05.004.
doi: 10.1016/j.urolonc.2018.05.004
[20]
Kumar N, Vasudeva P, Kumar A, Singh H, Sinha A. A prospective comparative study of channel photoselective vaporization of the prostate vs. channel transurethral resection of the prostate in patients with advanced prostate carcinoma. Minerva Urol Nefrol 2016; 68:330-6.
pmid: 27404375
[21]
Campobasso D, Marchioni M, Altieri V, Greco F, De Nunzio C, Destefanis P, et al. GreenLight photoselective vaporization of the prostate: one laser for different prostate sizes. J Endourol 2020; 34:54-62.
doi: 10.1089/end.2019.0478
pmid: 31617419
[22]
Salciccia S, Del Giudice F, Maggi M, Eisenberg ML, Chung BI, Conti SL, et al. Safety and feasibility of outpatient surgery in benign prostatic hyperplasia: a systematic review and metaanalysis. J Endourol 2021; 35:395-408.
doi: 10.1089/end.2020.0538
pmid: 33081521
[23]
Rosenhammer B, Lausenmeyer EM, Mayr R, Burger M, Eichelberg C. HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis. World J Urol 2018; 36:2035-41.
doi: 10.1007/s00345-018-2353-0
pmid: 29858700
[24]
Gong YG, Liu RM, Gao R. Photoselective vaporesection of the prostate with a front-firing lithium triborate laser: surgical technique and experience after 215 procedures. Eur Urol 2015; 67:1152-9.
doi: 10.1016/j.eururo.2014.12.021
[25]
Cindolo L, Marchioni M, Emiliani E, Francesco PDE, Primiceri G, Castellan P, et al. Bladder neck contracture after surgery for benign prostatic obstruction. Minerva Urol Nefrol 2017; 69:133-43.
doi: 10.23736/S0393-2249.16.02777-6
pmid: 27905698
